BioMarin Pharmaceutical Q3 2026 Earnings Preview
- BioMarin Pharmaceutical (BMRN) is scheduled to announce Q3 earnings results on Monday, November 2, after market close.
- The consensus EPS estimate is -$0.11 (-191.7% Y/Y), and the consensus revenue estimate is $1.02B (+31.4% Y/Y).
- Over the last 2 years, BMRN
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.